People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Other Health Care, Healthtech, Biotechnology, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vital Connect, Inc. | — | Other Health Care | Series B | $105.7M | $548.4M | 2017 |
| AccuVein Inc. | — | Other Health Care | Series B | $64.0M | $53.4M | 2020 |
| Cheetah Medical, Inc. | — | Healthtech | Series B | $59.6M | $74.4M | 2019 |
| Ambio Holdings, Inc. | — | Biotechnology | Series B | $24.0M | $952.5M | 2014 |
| Zipline Medical Inc | — | Other | Series B | $18.3M | $272.2M | 2015 |
| BEACON ENDOSCOPIC Corp | — | Other Health Care | Seed | $6.1M | $29.8M | 2011 |
| Cara Therapeutics, Inc. | — | Biotechnology | Series A | $4.9M | $3.6M | 2010 |
| Cortria Corp | — | Pharmaceuticals | Seed | $1.8M | $70.0M | 2009 |
| Biomedix Vascular Solutions Inc | — | Biotechnology | Pre-Seed | $682K | $37.7M | 2012 |
Stephen Reeders at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Reeders on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin McArdle | 2 | 3 |
| Christopher Hutchison | 2 | 2 |
| Robert Siegel | 1 | 13 |
| Brian Halak | 1 | 10 |
| Ed Hurwitz | 1 | 9 |
| Robert White | 1 | 8 |
| Christopher Thompson | 1 | 8 |
| Kevin Rakin | 1 | 7 |
| Eric Bednarski | 1 | 7 |
| Lewis Geffen | 1 | 6 |
| Amir Belson | 1 | 6 |
| Bosun Hau | 1 | 6 |
| Michael E Lewis | 1 | 4 |
| Brian Tinkham | 1 | 3 |
| Richard King | 1 | 3 |
| Martin Vogelbaum | 1 | 3 |
| Ron Goldman | 1 | 3 |
| CHRISTOPHER GABRIELI | 1 | 3 |
| Jeffrey L. Ives | 1 | 3 |
| Balaji Muralidhar | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.